Vascular Closure Articles & Analysis
11 news found
Department of Commerce’s United States Patent and Trademark Office (USPTO) has issued them Patent No. 11,224,414. Titled “Access Closure with Bleed Monitoring,” this key patent allows for embedding a vascular access closure device with the company’s proprietary bleed monitoring technology. ...
Axio Biosolutions, an integrated wound care company has announced FDA 510(k) clearance of its hemostatic product, Axiostat Patch that helps control moderate to severe bleeding in vascular procedures, surgical debridement sites, puncture sites and more. ...
Instylla, Inc., a privately held company developing minimally invasive liquid embolic products designed for use in peripheral vascular embolotherapy today announced closure of $25.4 million Series B financing. ...
The study is utilizing the VASCADE MVP Venous Vascular Closure System, which received U.S. Food and Drug Administration (FDA) approval in late 2018. VASCADE MVP is the only marketed vascular closure system proven and labeled specifically for procedures requiring multiple access site venous closure with 6-12 ...
. - October 30, 2019 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that positive results from the AMBULATE pivotal study demonstrating the safety and efficacy of the company’s VASCADE® MVP Venous Vascular Closure System compared to manual compression were published online in the ...
– December 18, 2018 – Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that the company has received PMA approval from the U.S. Food and Drug Administration (FDA) for the VASCADE® MVP Venous Vascular Closure System. VASCADE MVP is the first and only vascular ...
& Chicago - November 10, 2018 - Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced that VASCADE® MVP, the first vascular closure system designed specifically for multi-access venous closure following electrophysiology procedures such as arrhythmia ablation, met its ...
Asuncion, Paraguay, April 20, 2017 – Transluminal Technologies, LLC, a Syracuse, NY-based medical device company has announced today that they have successfully completed the First-in-Man clinical study of the velox LB large bore vascular closure device with 100% procedural success (10/10). Methods: Patients with a baseline common femoral artery (CFA) ...
Food and Drug Administration (FDA) has granted market clearance to Rex Medical’s bioresorbable Closer Vascular Sealing System (VSS) to achieve rapid hemostasis of femoral artery catheterizations. The vascular closure device consists of an insertion sheath, dilator and an implant contained in a delivery system. ...
Transluminal Technologies LLC. out of Syracuse, New York won the CE Mark for its velox CD Vascular Closure Device used to close arteriotomies following percutaneous femoral procedures. ...
Adrian Ebner MD, Transluminal Technologies presents the first successful use of the velox CD™ vascular closure device in a cohort of 14 patients. The innovative use of a biodegradable magnesium alloy to create a temporary mechanical closure promises to deliver an exciting step forward in rapid time-to-hemostasis, time-to-ambulation, and ...